Rosenberg, J. E., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R., … Sharma, P. (2016). Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. In Annals of Oncology (Vol. 27, p. vi271). https://doi.org/10.1093/annonc/mdw373.12

Rosenberg, J. E., P. Bono, J. Kim, P. Spiliopoulou, E. Calvo, R. Pillai, P. A. Ott, et al. “Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study.” In Annals of Oncology, 27:vi271, 2016. https://doi.org/10.1093/annonc/mdw373.12.

Rosenberg JE, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, et al. Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. In: Annals of Oncology. 2016. p. vi271.

Rosenberg, J. E., et al. “Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study.” Annals of Oncology, vol. 27, 2016, p. vi271. Scopus, doi:10.1093/annonc/mdw373.12.

Rosenberg JE, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai R, Ott PA, de Braud F, Morse M, Le D, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Sharma P. Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. Annals of Oncology. 2016. p. vi271.